We developed a monoclonal neutralizing antibody that specifically targets FABP4, which not only efficiently blocked FABP4-driven CSC functions, but also efficiently suppressed tumor formation in a MASLD-HCC mouse model. This evidence concerns the gene FABP4 and hepatocellular carcinoma.